PTCT PTC THERAPEUTICS, INC.

NEUTRAL Impact: 3/10 DEFA14A
Horizon immediate Filed Apr 20, 2026 Processed 1mo ago SEC 0001104659-26-045533
Proxy solicitation materials
Latest settled — T+20d
PTCT ▼ -0.68% at T+20d
NEUTRAL call ✗ call lost -0.68% · α vs SPY -5.59% · entry $70.63 → $70.15
Next anchor: T+60d in 5w
Currently $75.14 · +6.39% from $70.63 entry
Entry anchored
Apr 20, 03:59 PM ET
via Databento tick
T+1d
+0.31%
call +0.31% · α -0.71%
$70.85
settled 8w ago
T+5d
-0.52%
call -0.52% · α -1.61%
$70.26
settled 7w ago
T+20d
-0.68%
call -0.68% · α -5.59%
$70.15
settled 26d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors, including Jessica Chutter who was recently appointed to the board. This filing is a definitive proxy statement soliciting shareholder votes on director elections, auditor ratification, and executive compensation. The filing follows a recent 8-K filing announcing Chutter's appointment and other board/executive changes, suggesting these materials are part of an ongoing governance process.

Actionable Insight

Monitor for any subsequent filings that might indicate changes in board dynamics or executive compensation trends, though this specific filing represents standard annual governance procedures.

Key Facts

  • PTC Therapeutics is holding its 2026 annual meeting to elect four Class I directors: Jessica Chutter, Matthew B. Klein, Stephanie S. Okey, and Jerome B. Zeldis
  • The proxy statement solicits votes on three proposals: election of directors, ratification of Ernst & Young as auditors, and approval of executive compensation
  • This filing follows a March 25, 2026 Form 8-K announcing Jessica Chutter's appointment to the board and other executive changes
  • The filing is routine corporate governance documentation for the annual shareholder meeting

Financial Impact

No direct financial impact - this is a routine governance filing

governanceboard composition

Risk Factors

  • Potential for shareholder activism if there are concerns about board composition or executive pay
  • Risk of low shareholder turnout for the vote

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-045533
Document: 0001104659-26-045533-index-headers.html0001104659-26-045533
Document: 0001104659-26-045533-index.html0001104659-26-045533
Document: 0001104659-26-045533.txt0001104659-26-045533
8 reports for PTCT
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +10.07%Apr 28, 2026
Filters
Rows
Reports for PTCT — sortable, filterable
Type Now
Jun 9, 2026
3d ago
8-K
NEUTRAL ★ 2/10
$73.75 awaiting T+5awaiting T+5$75.14 (+1.88%)
May 19, 2026
24d ago
Insider Cluster
NEUTRAL ★ 2/10
$71.02 $71.05▲ +0.04%▼ −1.76%$75.14 (+5.80%)
May 15, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$70.15 $67.65▼ −3.56%▼ −5.18%$75.14 (+7.11%)
Apr 28, 2026
6w ago
8-K
BULLISH ★ 6/10
$64.55 $66.57▲ +3.13%▲ +0.02%$75.14 (+16.41%)
Apr 20, 2026
7w ago
DEFA14A
NEUTRAL ★ 3/10
$70.63 $70.26▼ −0.52%▼ −1.61%$75.14 (+6.39%)
Apr 1, 2026
10w ago
Insider Cluster
BEARISH ★ 5/10
$68.75 $70.85▼ −3.05%▲ +0.71%$75.14 (−9.29%)
Mar 5, 2026
14w ago
Insider Cluster
NEUTRAL ★ 3/10
$63.33 $63.36▲ +0.05%▲ +2.29%$75.14 (+18.65%)
Mar 5, 2026
14w ago
Insider Cluster
BEARISH ★ 6/10
$63.33 $63.36▼ −0.05%▼ −2.29%$75.14 (−18.65%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (48h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access